Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$337,136 Mln
Revenue (TTM)
$57,367 Mln
Net Profit (TTM)
$0 Mln
ROE
0.9 %
ROCE
6.1 %
P/E Ratio
81.4
P/B Ratio
230.7
Industry P/E
28.33
EV/EBITDA
26.5
Div. Yield
3.4 %
Debt to Equity
45.4
Book Value
$--
EPS
$2.4
Face value
--
Shares outstanding
1,766,400,000
CFO
$142,983.00 Mln
EBITDA
$134,251.00 Mln
Net Profit
$64,606.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
AbbVie (ABBV)
| 4.4 | 0.8 | -13.5 | 9.3 | 10.3 | 14.1 | 10.6 |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P 100
| 0.7 | 1.3 | 6.7 | 10.5 | 20.5 | 15.5 | 12.2 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
AbbVie (ABBV)
| 14.5 | -4.1 | 19.4 | 32.4 | 27.7 | 1.5 | -1.0 |
|
S&P 100
| 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 | -5.8 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
AbbVie (ABBV)
|
185.5 | 337,135.9 | 57,367.0 | 4,195.0 | 14.0 | 112.4 | 81.4 | 230.7 |
| 289.6 | 158,924.4 | 34,126.0 | 5,933.0 | 24.2 | 86.4 | 26.9 | 25.6 | |
| 46.8 | 96,116.8 | 47,636.0 | 5,419.0 | 17.1 | 31.3 | 17.6 | 5.8 | |
| 785.0 | 735,568.9 | 49,003.2 | 11,106.4 | 29.5 | 74 | 65.8 | 46.7 | |
| 108.0 | 137,864.2 | 28,734.0 | 5,965.0 | 27.2 | 31.7 | 23.3 | 7.2 | |
| 150.7 | 377,994.8 | 89,331.0 | 21,810.0 | 30.7 | 29.4 | 17.3 | 4.8 | |
| 728.9 | 91,024.9 | 359,051.0 | 3,295.0 | 0.9 | -162.9 | 28.3 | 5.0 | |
| 79.3 | 205,176.1 | 63,922.0 | 17,434.0 | 35.5 | 37.5 | 11.8 | 4.2 | |
| 23.9 | 139,519.0 | 62,463.0 | 7,866.0 | 16.6 | 8.6 | 17.7 | 1.5 | |
| 155.1 | 73,183.3 | 9,286.0 | 2,518.0 | 37.6 | 50.7 | 29.5 | 15.7 |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal... Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 Read more
Chairman & CEO
Mr. Richard A. Gonzalez
Executive Chairman
Mr. Richard A. Gonzalez
Headquarters
North Chicago, IL
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of AbbVie Inc (ABBV) stood at $ 172,568 Mln as on 31-Mar-25
The share price of AbbVie Inc (ABBV) is $185.49 (NYSE) as of 18-Jun-2025 16:10 EDT. AbbVie Inc (ABBV) has given a return of 10.29% in the last 3 years.
AbbVie Inc (ABBV) has a market capitalisation of $ 337,136 Mln as on 18-Jun-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of AbbVie Inc (ABBV) is 230.73 times as on 18-Jun-2025, a 4677% premium to its peers’ median range of 4.83 times.
The P/E ratio of AbbVie Inc (ABBV) is 81.35 times as on 18-Jun-2025, a 187% premium to its peers’ median range of 28.33 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the AbbVie Inc (ABBV) and enter the required number of quantities and click on buy to purchase the shares of AbbVie Inc (ABBV).
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
The CEO & director of Mr. Richard A. Gonzalez. is AbbVie Inc (ABBV), and CFO & Sr. VP is Mr. Richard A. Gonzalez.
There is no promoter pledging in AbbVie Inc (ABBV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
72,592
|
|
|
37,357
|
|
|
20,169
|
|
|
15,691
|
|
|
13,918
|
|
|
13,596
|
|
|
10,208
|
|
|
8,972
|
|
|
7,405
|
| AbbVie Inc. (ABBV) | Ratios |
|---|---|
|
Return on equity(%)
|
112.37
|
|
Operating margin(%)
|
13.97
|
|
Net Margin(%)
|
7.31
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of AbbVie Inc (ABBV) was $0 Mln.
$0.01
(
